A new alternative treatment in COPD: phosphodiesterase-4 inhibitors
[ X ]
Tarih
2011
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turkish Assoc Tuberculosis & Thorax
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Chronic obstructive pulmonary disease (COPD) is a disease which is characterized with progressive airflow obstruction and abnormal inflammatory response caused by noxious gases and particles. Recently oral phosphodiesterase-4 (PDE-4) inhibitors which block activation of inflammatory cells, are experimented as a new approach. Last studies showed that these drugs improve symptoms, pulmonary functions and quality of life, reduce the numbers of acute attacks, suppress bronchial inflammation in COPD. However these drugs lead to adverse reactions such as vomiting, diarrhea and headache. In this review we discussed roflumilast (Daxas) which was accepted by Food and Drug Administration (FDA), included in treatment of sever COPD in The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline.
Açıklama
Anahtar Kelimeler
Copd, Inflammation, Phosphodiesterase-4 Inhibitors
Kaynak
Tuberkuloz Ve Torak-Tuberculosis and Thorax
WoS Q Değeri
N/A
Scopus Q Değeri
Q3
Cilt
59
Sayı
3
